BRAF and cutaneous melanoma: We hypothesized that associating the NGS-identified gene mutations to their specific associated disease pathologies (e.g., lung adenocarcinoma with EGFR mutations or cutaneous melanoma with NRAS or BRAF mutations) would demonstrate higher concordance with hotspot mutations recognized by the Idylla system and may also uncover additional clinically significant NGS-identified gene mutations not detected by Idylla.